ANNAPOLIS, Md., March 20 /PRNewswire-FirstCall/ -- PharmAthene, Inc.
(Amex: PIP) a biodefense company developing medical countermeasures against
biological and chemical threats, today reported the company will delay its
earnings release for the full year ended December 31, 2007. The earnings
release was previously scheduled for today, March 20, 2008. PharmAthene
will schedule the new date and time of its earnings release and conference
call at a later time.
The conference call originally scheduled to discuss earnings will occur
at 4:30 pm E.T. today and will focus on the Avecia acquisition announced
earlier today.
About PharmAthene, Inc.
PharmAthene (Amex: PIP) was formed to meet the critical needs of the
United States and its allies by developing and commercializing medical
countermeasures against biological and chemical weapons. PharmAthene's lead
programs include Valortim(TM) for the prevention and treatment of anthrax
infection and Protexia(R) for the prevention and treatment of morbidity and
mortality associated with exposure to chemical nerve agents. For more
information on PharmAthene, please visit http://www.PharmAthene.com.
SOURCE PharmAthene, Inc.
 back to top
Related links:
http://www.pharmathene.com
CONTACT:
Stacey Jurchison of PharmAthene, Inc.,
+1-410-269-2610, JurchisonS@PharmAthene.com
|
